This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.
本发明涉及一种新颖的融合
三环化合物,它们是哺乳动物
雷帕霉素靶向蛋白(mTOR)激酶的
抑制剂,也被称为FRAP、RAFT、RA
PT或
SEP,并且在治疗细胞增殖性疾病,例如癌症和其他增殖性疾病方面有用。